IPO - Aptevo Therapeutics Inc.

Form Type: S-1

Filing Date: 2025-05-13

Corporate Action: Ipo

Type: New

Accession Number: 000095017025070551

Filing Summary: Aptevo Therapeutics Inc. filed a registration statement on Form S-1 with the SEC on May 13, 2025, for a public offering of up to 3,529,420 shares of its Common Stock. The shares are being registered for resale by certain stockholders who received the shares as part of a private placement alongside the issuance of common stock purchase warrants. The offering price for the shares, along with the associated warrants, was $1.19 per share. Aptevo’s Common Stock is traded on the Nasdaq Capital Market under the symbol 'APVO'. The company is a clinical-stage biotechnology firm focusing on developing immunotherapy candidates for cancer treatment, with two clinical candidates and several preclinical candidates currently in development. Aptevo plans to grow its business through advancing unique drug candidates employing their ADAPTIR and ADAPTIR-FLEX platforms, aimed at enhancing immune responses against cancer. The prospectus outlines the company's business overview, product pipeline, risk factors, and use of proceeds, although Aptevo will not receive any proceeds from the resale of the registered shares. This IPO indicates a significant step in Aptevo’s efforts to attract further investment and continue its research and clinical trials.

Form Type: 424B4

Filing Date: 2025-04-28

Corporate Action: Ipo

Type: New

Accession Number: 000095017025058974

Filing Summary: On April 28, 2025, Aptevo Therapeutics Inc. filed a prospectus supplement under Rule 424(b)(5) related to an At The Market Offering Agreement with Roth Capital Partners, allowing the company to sell shares of its common stock valued up to $50,000,000 over time. This offering is subject to market conditions, with Roth acting as the sales agent and earning a commission of 3.0% on the gross proceeds. As of the filing date, the aggregate market value of outstanding common stock held by non-affiliates is approximately $21,189,735 based on reported share prices. The funds raised from the offering are intended primarily for research, development, and general corporate purposes, as outlined in the document. This strategy reflects Aptevo's position as a clinical-stage biotechnology company focused on immunotherapy for cancer treatment, emphasizing its innovative approaches and the risks associated with investing in their stock.

Form Type: 424B4

Filing Date: 2025-04-22

Corporate Action: Ipo

Type: New

Accession Number: 000095017025056475

Filing Summary: Aptevo Therapeutics Inc. is offering 2,324,000 shares of its common stock, priced at $0.862 per share, under a registered direct offering as detailed in the prospectus supplement filed on April 21, 2025. The offering, arranged by Roth Capital Partners, LLC as the exclusive placement agent, will result in gross proceeds of approximately $2,003,288 before expenses, with an expected closing date of April 22, 2025. The offering represents less than one-third of the aggregate market value of Aptevo's outstanding common stock held by non-affiliates, adhering to SEC guidelines. Aptevo specializes in developing immunotherapy candidates for cancer treatment, boasting innovative technologies and promising clinical candidates like mipletamig for acute myelogenous leukemia and ALG.APV-527 for solid tumors. The prospectus also emphasizes the risks involved in investing in common stock, including market conditions and corporate performance. Additionally, the document highlights the company's strategic growth plans and the intended use of proceeds, primarily for research and development activities.

Form Type: 424B4

Filing Date: 2025-04-04

Corporate Action: Ipo

Type: New

Accession Number: 000095017025050924

Filing Summary: Aptevo Therapeutics Inc. is conducting a registered direct offering of 1,764,710 shares of common stock at a price of $1.19 per share, along with two Common Warrants for each share purchased in a concurrent private placement. Each Common Warrant allows the holder to purchase one additional share of common stock at the same price, which requires stockholder approval for exercise. The offering is projected to generate approximately $1.9 million in net proceeds, intended for working capital and further development of product candidates. The Common Warrants have an initial exercise price of $1.19 and expire five years after stockholder approval. The company has engaged Roth Capital Partners, LLC as the exclusive placement agent for this offering. As of April 3, 2025, Aptevo’s common stock is listed on the Nasdaq Capital Market under the symbol 'APVO' with a reported closing price of $1.99 per share on that date.

Form Type: S-1/A

Filing Date: 2025-04-01

Corporate Action: Ipo

Type: Update

Accession Number: 000095017025048016

Filing Summary: Aptevo Therapeutics Inc. has filed an amendment to its S-1 registration statement, proposing a public offering of up to 15,086,207 shares of common stock, accompanied by pre-funded and common warrants. These securities are aimed at facilitating growth and funding for the company’s drug development pipeline. The registration also includes significant details regarding terms like the exercise prices of warrants, adjustments based on stockholder approval, and restrictions on further issuances for a specified period. The filing emphasizes the company's focus on developing novel immunotherapy candidates, with ongoing clinical trials aimed at treating various types of cancer. Aptevo is also navigating regulatory challenges and market requirements to ensure compliance and successful funding.

Form Type: S-1/A

Filing Date: 2025-03-27

Corporate Action: Ipo

Type: New

Accession Number: 000095017025045728

Filing Summary: On March 27, 2025, Aptevo Therapeutics Inc. filed an amendment (S-1/A) to its registration statement under the Securities Act of 1933 to offer up to 12,987,013 shares of common stock and various warrants including Series A and Series B warrants alongside pre-funded warrants. The company aims to proceed with a public offering as soon as practicable after the registration statement becomes effective. The shares offered are at an assumed public offering price of $1.54 per share. Additionally, the company has stated that proceeds from this offering will support their clinical development programs, including lead candidates mipletamig and ALG.APV-527, aimed at treating different forms of cancer. Notably, the filing details mechanisms for serious investor participation, while also discussing the exercise pricing and the conditions surrounding investor approvals required for warrant exercises. Aptevo aims to leverage their proprietary platform technologies to develop innovative immunotherapies to address challenging cancer types while planning to navigate the risks associated with their operations and funding requirements. The offering is intended to be completed by May 15, 2025, unless terminated earlier. SEC has not yet approved this offering, indicating regulatory consideration is still pending.

Form Type: S-1/A

Filing Date: 2025-03-27

Corporate Action: Ipo

Type: New

Accession Number: 000095017025046199

Filing Summary: Aptevo Therapeutics Inc. is filing an amendment to its registration statement for a public offering of securities, specifically aiming to sell up to 12,987,013 shares of common stock along with pre-funded warrants and Series A and B Warrants. These warrants entitle purchasers to purchase additional shares of common stock. The offering is structured to include a reasonable best efforts public offering at an assumed price of $1.54 per share. The series of warrants have specific terms regarding exercise pricing and stockholder approvals. Notably, holders of Series B Warrants have the option of a zero exercise price, which could result in the issuance of a substantial number of additional shares. The document outlines the risks associated with the investment, details about the underwriting and placement agent, and other regulatory notices. The expected termination date for the offering, barring any termination by the issuer, is noted as May 15, 2025. Additionally, the company's common stock is currently listed on the Nasdaq Capital Market under the symbol 'APVO.'

Form Type: S-1

Filing Date: 2025-03-03

Corporate Action: Ipo

Type: New

Accession Number: 000095017025030286

Filing Summary: Aptevo Therapeutics Inc. is filing a registration statement under the Securities Act of 1933. The company aims to conduct a public offering of up to 1,557,632 shares of common stock, along with various warrants. The offering includes pre-funded warrants for those whose purchases may cause them to exceed 4.99% ownership of the company. The offering is designed to raise funds for clinical development of Aptevo's cancer therapies, including mipletamig and ALG.APV-527, which target different cancer types. The company emphasizes its innovative ADAPTIR® platforms for engineering therapeutic candidates and highlights favorable preliminary clinical results from ongoing trials, stating a 100% complete remission rate for the lead candidate in a recent cohort. The document outlines terms of the offering, risks associated with the investment, and the company’s strategy to collaborate with other entities to support its development. Additionally, the offering will terminate by April 15, 2025, unless otherwise decided by the company.